Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib
- 142 Downloads
Olaparib (OLA) is a poly ADP ribose polymerase (PARP) inhibitor approved for germline BRCA-mutated (gBRCAm) advanced ovarian cancer and breast cancer. Low oral bioavailability of this drug requires increase in the dose and frequency causing haematological toxicity in the patients. The purpose of this study is to prepare different nano-formulations of OLA lipospheres (LP) by melt dispersion and nano-suspensions (NSP) by solvent evaporation (SE) and wet milling (WM) techniques and compare oral bioavailability of these formulations. Size of the nano-formulations OLA-LP, OLA-NSPSE and OLA-NSPWM were found to be 126.71 ± 4.54, 128.6 ± 2.34 and 531.1 ± 5.34 nm with polydispersity index below 0.3. In vitro release studies were performed by dialysis bag method where the sustained drug release was observed from nano-formulations until 9 h with Higuchi for OLA suspended in 2.5% w/v sodium carboxy methyl cellulose (OLA-SP), OLA-LP and OLA-NSPWM and Peppas for OLA-NSPSE-based drug release kinetics. In vivo pharmacokinetic studies, haematological toxicity and distribution studies were performed on rats. Results showed that there was an improvement in Cmax, AUCtotal, t1/2 and MRT by OLA nano-formulations when compared with OLA-SP. OLA-SP has shown reduction in WBC, platelets and lymphocytes at 12 and 36 h time points; however, no reduction in cell count was observed with OLA nano-formulations. Distribution studies proved FITC nano-formulations were most rapidly absorbed and distributed when compared with FITC-loaded suspension. From the above results, it was concluded that OLA nano-formulations can be an alternative to enhance the oral bioavailability and to reduce the haematological toxicity of OLA.
KEY WORDSOlaparib PARP inhibitor Nano-formulations Bioavailability
Polyadenosine 5′diphosphoribose polymerase
High-performance liquid chromatography
Nano-suspension by wet milling
Nano-suspension by solvent evaporation
Dynamic light scattering
Poly dispersity index
Authors are thankful to Director, NIPER-Hyderabad for providing required facilities, support and encouragement throughout the project.
Financial assistance for this work was provided by Ministry of Chemicals & Fertilizers, Govt. of India.
Compliance with Ethical Standards
Complying with Ethics of Experimentation
The animal protocol was approved by Institutional Animal Ethics Committee (IAEC) of National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, India. Animal experiments were carried out in accordance with the guidelines of CPCSEA, India.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Races A. SEER cancer statistics review 1973–1999. Bethesda: National Cancer Institute; 2002.Google Scholar
- 4.Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.PubMedPubMedCentralCrossRefGoogle Scholar
- 13.Butler T, Maravent S, Boisselle J, Valdes J, Fellner C. A review of 2014 cancer drug approvals, with a look at 2015 and beyond. Pharm Ther. 2015;40(3):191–205.Google Scholar
- 14.Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.PubMedCrossRefGoogle Scholar
- 24.Thummar M, Kuswah BS, Samanthula G, Bulbake U, Gour J, Khan W. Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products. J Pharm Biomed Anal. 2018;160:89–98.PubMedCrossRefGoogle Scholar
- 27.Kommineni N, Saka R, Bulbake U, Khan W. Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. Chem Phys Lipids. 2018.Google Scholar
- 35.Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–23.Google Scholar
- 36.Sharma AK, Keservani RK, Kesharwani RK. Nanobiomaterials: applications in drug delivery: CRC Press; 2018.Google Scholar
- 44.D’Souza S. A review of in vitro drug release test methods for nano-sized dosage forms. Adv Pharm. 2014;2014.Google Scholar